ESI-09

Catalog No.S7499 Batch:S749901

Print

Technical Data

Formula

C16H15ClN4O2
Molecular Weight 330.77 CAS No. 263707-16-0
Solubility (25°C)* In vitro DMSO 66 mg/mL (199.53 mM)
Ethanol 20 mg/mL (60.46 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
10%Ethanol 10%Tween80 80%ddH2O
1.0mg/ml Taking the 1 mL working solution as an example, add 100 μL of 10 mg/ml clarified ethanol stock solution to 100 μL of Tween 80, mix evenly to clarify it; then continue to add 800 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description ESI-09 is a specific exchange protein directly activated by cAMP (EPAC) inhibitor with IC50 of 3.2 μM and 1.4 μM for EPAC1 and EPAC2, respectively, >100-fold selectivity over PKA.
Targets
EPAC2 [1]
(Cell-free assay)		 EPAC1 [1]
(Cell-free assay)
1.4 μM 3.2 μM
In vitro ESI-09, a novel non-cyclic nucleotide EPAC antagonist, that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells. On the other hand, ESI-09 fails to suppress epidermal growth factor (EGF)-induced phosphorylation of Akt in AsPC1 cells. In pancreatic cancer cells, ESI-09 inhibits cells migration and invasion through decreasing 007-AM-induced cell adhesion dose-dependently. [1] ESI-09 significantly reduces intracellular and total bacterial counts in human umbilical vein endothelial cells. [2] ESI-09 effectively antagonizes Schwann cells (SC) differentiation induced by CPT-cAMP as well as the formation of myelin. In SC-neuron cultures, ESI-09 dramatically reduces the number of O1 positive and MBP positive SCs without compromising the health of the neurons or the SCs themselves. [3]
In vivo ESI-09 (10 mg/kg/d, i.p.), via pharmacological inhibition of EPAC1, protects WT C57BL/6 mice from fatal SFG rickettsiosis. [2]

Protocol (from reference)

Animal Study:[2]
  • Animal Models

    Epac1+/+ mice

  • Dosages

    10 mg/kg/d

  • Administration

    i.p.

Customer Product Validation

, , Brain Behav Immun, 2016, 58:118-129.

Data from [Data independently produced by , , Biomed Pharmacother, 2019, 109:1268-1275]

Data from [Data independently produced by , , Acta Diabetol, 2017, 54(6):581-591]

Data from [Data independently produced by , , Inflammation, 2018, 41(3):1093-1103]

Selleck's ESI-09 has been cited by 11 publications

Inhibition of exchange proteins directly activated by cAMP as a strategy for broad-spectrum antiviral development [ J Biol Chem, 2023, 299(6):104749] PubMed: 37100284
Inhibition of exchange proteins directly activated by cAMP as a strategy for broad-spectrum antiviral development [ J Biol Chem, 2023, 299(6):104749] PubMed: 37100284
Terbutaline attenuates LPS-induced injury of pulmonary microvascular endothelial cells by cAMP/Epac signaling [ Drug Dev Res, 2021, 10.1002/ddr.21901] PubMed: 34846077
Knockdown of GPSM1 Inhibits the Proliferation and Promotes the Apoptosis of B-Cell Acute Lymphoblastic Leukemia Cells by Suppressing the ADCY6-RAPGEF3-JNK Signaling Pathway [ Pathol Oncol Res, 2021, 27:643376] PubMed: 34257610
Exchange protein directly activated by cAMP (Epac) 1 plays an essential role in stress-induced exercise capacity by regulating PGC-1α and fatty acid metabolism in skeletal muscle. [ Pflugers Arch, 2020, 472(2):195-216] PubMed: 31955265
Curcumin pretreatment protects against hypoxia/reoxgenation injury via improvement of mitochondrial function, destabilization of HIF-1α and activation of Epac1-Akt pathway in rat bone marrow mesenchymal stem cells [Wang X, et al. Biomed Pharmacother, 2019, 109:1268-1275] PubMed: 30551377
Protective Effect of Quercetin in LPS-Induced Murine Acute Lung Injury Mediated by cAMP-Epac Pathway [Wang XF, et al. Inflammation, 2018, 41(3):1093-1103] PubMed: 29569077
Activation of Epac alleviates inflammation and vascular leakage in LPS-induced acute murine lung injury [Wang X, et al. Biomed Pharmacother, 2017, 96:1127-1136] PubMed: 29174852
The microRNA-7-mediated reduction in EPAC-1 contributes to vascular endothelial permeability and eNOS uncoupling in murine experimental retinopathy. [Garcia-Morales V, et al. Acta Diabetol, 2017, 54(6):581-591] PubMed: 28353063
Bile Acids Control Inflammation and Metabolic Disorder through Inhibition of NLRP3 Inflammasome [Guo C, et al. Immunity, 2016, 45(4):944] PubMed: 27760343

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.